Fulcrum Therapeutics, Inc. Common Stock
Symbol: FULC (NASDAQ)
7.66
▲ (11.34%) 0.780
Company Description:
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Key Stats
- Today's Open: $6.9
- Today's High: $7.885
- Today's Low: $6.825
- Today's Volume: 599.06K
- Yesterday Close: $6.88
- Yesterday High: $7.01
- Yesterday Low: $6.35
- Yesterday Volume: 431.75K
- Last Min Volume: 10
- Last Min High: $7.66
- Last Min Low: $7.66
- Last Min VWAP: $7.66
Company Profile
- Name: Fulcrum Therapeutics, Inc. Common Stock
- Website: https://www.fulcrumtx.com
- Listed Date: 2019-07-18
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0001680581
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $414.34M
- Round Lot: 100
- Outstanding Shares: 54.09M
- Asset Type: CS
RECENT FILINGS FOR FULC
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-28 | 8-K | View |
| 2025-08-12 | SCHEDULE 13G/A | View |
| 2025-07-29 | 10-Q | View |
| 2025-07-29 | 8-K | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-27 | 8-K | View |
| 2025-05-09 | 4 | View |
| 2025-05-07 | DEFR14A | View |
| 2025-05-02 | SCHEDULE 13G/A | View |
| 2025-05-01 | 10-Q | View |
| 2025-05-01 | 8-K | View |
| 2025-04-30 | ARS | View |
| 2025-04-30 | DEFA14A | View |
Latest News on FULC